Proxen plus
Download as PPT, PDF3 likes2,310 views
This presentation discusses Proxen Plus, a fixed-dose combination drug containing naproxen and esomeprazole. Proxen Plus is designed to release esomeprazole first in the stomach to block acid production, followed by release of enteric-coated naproxen in the small intestine. It is indicated for conditions requiring NSAID treatment like musculoskeletal disorders, where lowering gastric acidity can reduce risks. Studies show Proxen Plus is as effective as other NSAIDs for pain relief, while providing better gastrointestinal safety over long-term use up to one year. The presentation promotes Proxen Plus to rheumatologists, surgeons and other physicians as a convenient, cost-effective option for patients at risk of NSAID-associated ul
Proxen plus
- 3. Combinations always does the best
- 4. Often Taking Naproxen Single is a Danger
- 7. Dual Action, Dual Impact
- 8. Naproxen & Esomeprazole Modified-release tablet containing enteric-coated (gastro- resistant) naproxen and film-coated esomeprazole.
- 9. Indications
- 11. Mechanism of Action of Naproxen Sodium
- 12. NSAIDs Action
- 13. Naproxen Works on Selected Areas of body
- 14. M/A of Proxen plus • Proxen Plus is a fixed dose combination of the proton pump inhibitor esomeprazole magnesium, with the non- steroidal anti-inflammatory drug (NSAID) naproxen in a single tablet. Proxen Plus has been developed as a delayed release tablet whereby esomeprazole (20 mg) is released first in the stomach, prior to the dissolution of enteric-coated naproxen (500 mg) in the small intestine. The mechanism of action of the naproxen, like that of other NSAIDs, is not completely understood but may be related to prostaglandin synthetase inhibition. By acting specifically on the proton pump, esomeprazole blocks the final step in acid production, thus reducing gastric acidity.
- 15. Dosing Information • One tablet to be swallowed whole twice daily, taken 30 minutes before food.
- 16. Administration
- 17. Indigestion ,impaired sense of taste Inflammation of sinuses Back pain, dizziness, cough,constipation Burning or discomfort of stomach, gas, headache Side Effects
- 18. Cautions
- 20. Why Not Omeprazole, Why we combine Esomeprazole
- 21. Present Market Scenario Products Name Company Market Share Sales Growth LaunchingYear DINOVO Beximco 1.25% 84,145,873 22.48% 2011 XENOLE Square 1.03% 69,058,731 7.74% 2012 Naprosyn Plus Radiant 16.95% 145,535,325 25.06% 2012 NAPROX PLUS Eskayef 3.33% 48,165,368 17.19% 2013 NAPRO-A- PLUS ACME 3.39% 49,054,797 33.81% 2012
- 22. Brand Analysis Brand Name Contains Dosage Form Manufacturer Price(Tk.) DEMOVO 375 Naproxen sodium 375mg & esomeprazole 20mg/tablet Tablet Delta Pharma Limited 375mg x 24s pack: 192.00 MRP DEMOVO 500 Naproxen sodium 500mg & esomeprazole 20mg/tablet Tablet Delta Pharma Limited 500mg x 16s pack: 160.00 MRP DINOVO 375/20 Naproxen sodium 375mg & esomeprazole 20mg/tablet Tablet Beximco Pharmaceuticals Ltd 375mg x 50s pack: 400.00 MRP DINOVO 500/20 Naproxen sodium 500mg & esomeprazole 20mg/tablet Tablet Beximco Pharmaceuticals Ltd 500mg x 50s pack: 500.00 MRP NAPXON 375 Naproxen sodium 375mg & esomeprazole 20mg/tablet Tablet Ziska Pharmaceuticals Ltd 375mg x 32s pack: 256.00 MRP NAPXON 500 Naproxen sodium 500mg & esomeprazole 20mg/tablet Tablet Ziska Pharmaceuticals Ltd 500mg x 32s pack: 320.00 MRP NESO-375 Naproxen sodium 375mg & esomeprazole 20mg/tablet Tablet Aristopharma Ltd. 375mg x 40s pack: 320.00 MRP NESO-500 Naproxen sodium 500mg & esomeprazole 20mg/tablet Tablet Aristopharma Ltd. 500mg x 40s pack: 400.00 MRP PROGESIC 375 Naproxen sodium 375mg & esomeprazole 20mg/tablet Tablet Incepta Pharmaceuticals Ltd 375mg x 30s pack: 240.00 MRP PROGESIC 500 Naproxen sodium 500mg & esomeprazole 20mg/tablet Tablet Incepta Pharmaceuticals Ltd 500mg x 28s pack: 280.00 MRP
- 23. Key promotional Points 1) FDA approves this to treat Musculoskeletal Disorders after vigorous Study 2) Comparative effectiveness and safety of Proxen Plus against both meloxicam and celecoxib would be required for the following outcomes: *Pain *Gastrointestinal outcomes *Cardiovascular outcomes 3) 100% satisfactory for those patients who are at a risk of NSAID-associated gastric and/or duodenal ulcers and where lower doses of naproxen or other NSAIDs are not sufficient.
- 24. Key promotional Points • Safe for long term use up to one year. • Convenient & cost effective.
- 25. Target Customers • Rheumatologists • Arthritis Specialist • Orthopedics • Surgeons • Gastroenterologists • Medicine Specialists • GPs
- 27. Lowest dose can achieve the goals